Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

FBRX holding history

Forte Biosciences, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

FBRX overviewAll 13F holders of FBRXFull Q2 2026 holdings

Shares (Q2 2026)
164,557
Value
$3.50M
% of portfolio
<0.1%
Quarters held
21
Since Q1 2021
Holdings of FBRX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026164,557$3.50M<0.1%+144,107+704.7%AddedHolders
Q1 202620,450$529.7K<0.1%−4,374−17.6%ReducedHolders
Q4 202524,824$677.0K<0.1%+23,264+1,491.3%AddedHolders
Q3 20251,560$23.4K<0.1%+1,559+155,900.0%AddedHolders
Q2 20251$13<0.1%−526−99.8%ReducedHolders
Q1 2025527$4.09K<0.1%+527NewHolders
Q4 20240$00.0%−1,606−100.0%Sold outHolders
Q3 20241,606$8.98K<0.1%+634+65.2%AddedConverted for a 1-for-25 splitHolders
Q2 202424,310$13.1K<0.1%+24,277+73,566.7%AddedHolders
Q1 202433$23<0.1%−113−77.4%ReducedHolders
Q4 2023146$120<0.1%−2,325−94.1%ReducedHolders
Q3 20232,471$1.64K<0.1%+2,438+7,387.9%AddedHolders
Q2 202333$34<0.1%−9,487−99.7%ReducedHolders
Q1 20239,520$9.62K<0.1%+7,805+455.1%AddedHolders
Q4 20221,715$1.72K<0.1%+1,682+5,097.0%AddedHolders
Q3 202233$00.0%−1,859−98.3%ReducedHolders
Q2 20221,892$2.00K<0.1%−279−12.9%ReducedHolders
Q1 20222,171$3.00K<0.1%−9,344−81.1%ReducedHolders
Q4 202111,515$25.0K<0.1%+11,215+3,738.3%AddedHolders
Q3 2021300$1.00K<0.1%−322−51.8%ReducedHolders
Q2 2021622$21.0K<0.1%+322+107.3%AddedHolders
Q1 2021300$10.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.